>>no real filter and that kind of stuff. But you're also an entrepreneur, right? And you know the business, you've been in software, you detect business. I'm instructing you get a lot of pictures, this entertainment business on our show, we're a bubble. We don't do a lot of tech deals that were talking because it's boring tv tech people love tech consumers love the benefit of text. No consumer opens up their iphone and says, oh my gosh, I love the technology behind my, what's it been like being on the shark tank? You know, filming is fun and hang out just fun and it's fun to be a celebrity at first your head gets really big and you get a really good tables at restaurants and who says texas has got a little possessed more skin in the game today in charge of his destiny. Great robert Herjavec. No, these two stars cube alumni >>welcome back to the cubes coverage of A W. S. Public sector seven. I'm john for your host of the cube got a great segment here on healthcare startup accelerators of course. Sandy carter is co hosting media. This one Vice President Aws. She's awesome on the cuBA and jennifer Blumenthal co founder and C of one record entrepreneur, very successful. Thanks for coming on jennifer. Thank good to see you. Sandy thanks for joining me again. You >>are most welcome, >>jennifer. Before we get into the whole accelerated dynamic, just take a minute to explain what you guys do. One record. >>Sure. So one record is a digital health company that enables users to access aggregate and share their healthcare information. So what that means is we help you as a person get your data and then we also help companies who would like to have workflows were consumers in the loop to get their data. So whether they're sharing it with a provider, researcher payer. >>So, Sandy, we've talked about this amazon web services, healthcare accelerator cohort batches. What do you call cohort batches? Cohorts explain what's going on with the healthcare accelerator? >>Yeah. So, um, we decided that we would launch and partner an accelerator program and accelerator program just provides to a start up a little bit extra technical help. A little bit extra subject matter expertise and introductions to funders. And so we decided we were going to start one for health care. It's one of the biggest disruptive industries in public sector. Um, and so we weren't sure how it's gonna go. We partnered with Kids X. Kids X is part of the Los Angeles system for medical. And so we put out a call for startups and we had 427 startups, we were told on average and accelerating it's 50-100. So we were blown away 31 different countries. So it was really amazing. And then what we've been doing is down selecting and selecting that Top 10 for our first cohort. So we're going from 427 down to 10. And so obviously we looked at the founders themselves to see the quality of the leadership of the company, um the strength of their technology and the fit of the technology into the broader overall healthcare and healthcare ecosystem. And so we were thrilled that jennifer and one record was one of the top 10 start ups in this space that we chose to be in the, in the cohort. And so now we're going to take it to the six weeks intensive where we'll do training, helping them with AWS, provide them A W. S. Credits and then Kid X will also provide some of the health care uh subject matter >>expertise as well. Can I get some of those credits over here to maybe? >>Yes, you can actually, you can talk to me don you can't >>Talk to me, Jennifer, I gotta ask you. So you're an entrepreneur. So doing start doing cos it's like a roller coaster. So now to make the top 10 but also be in the area of his accelerator, it's a partnership, right? You're making a bet. What's your take on all this? >>Well, we've always been partners with a W. S. We started building on AWS in the very beginning. So when I was setting up the company a huge decision early on with infrastructure and when I saw the launch of the accelerator, I had to apply because we're at the point in the company that we're growing and part of growing is growing with the VW. So I was really excited to take advantage of that opportunity and now in the accelerator, it's more of thinking about things that we weren't thinking about the services that we can leverage to fill in the gaps within our platform so we can meet our customers where they are >>using award winning MSP cloud status city, your partners, great relationship with the ecosystem. So congratulations Sandi. What's the disruption for the healthcare? Because right now education and health care, the two top areas we're seeing and we're reporting on where cloud scale developed two point or whatever buzzword digital transformation you want to use is impacting heavily healthcare industry. There's some new realities. What's your, what's your vision, what's your view? >>Hey john before she does that, I have to give a plug to Claudius city because they just made premier partner as well, which is a huge deal. Uh and they're also serving public sector. So I just wanted to make sure that you knew that too. So you can congratulate. Go ahead, jennifer >>Well, so if I zoom in, I think about a P. I. S. Every day, that's what I think about and I think about microservices. So for me and for one record, what we think about is legislation. So 21st century Cures act says that you as a consumer have to be able to access your healthcare data from both your providers and from your players and not just your providers, but also the underlying technology vendors and H. I. E. S. H. I am and it's probably gonna extend to really anyone who plays within the healthcare ecosystem. So you're just going to see this explosion of A. P. I. S. And we're just your one of that. I mean for the payers that we went into effect on july 1st. So I mean when you think about the decentralization of healthcare where healthcare is being delivered plus an api economy, you're just going to have a whole new model developing and then throwing price transparency and you've got a whole new cake. >>I'm smiling because I love the peacocks. In fact, last night I shouldn't have tweeted this but there's a little tweet flames going on around A. P. Is being brittle and all this stuff and I said, hey developer experience about building great software apps are there for you. It's not a glue layer by itself. You got to build software around the so kind of a little preaching to the younger generation. But this health care thing is huge because think about like old school health care, it was anti ap I was also siloed. So what's your take on has the culture is changing health care because the user experience, I want my records, I want my privacy, I want to maintain everything confidential but access. That's hard. >>I think well health care to be used to just be paper was forget about a. P. I. Is it was just paper records. I think uh to me you think about uh patient journey, like a patient journey starts with booking an appointment and then everything after that is essentially an api call. So that's how I think about it is to all these micro transactions that are happening all the time and you want your data to go to your health care provider so they can give you the proper care, you want your data to go to your pair so they can pay for your care and then those two stakeholders want your data so that they can provide the right services at the right time to the right channel. And that is just a series of api calls that literally sits on a platform. >>What's interesting, I'd love to get your take on the where you think the progress bar is in the industry because Fintech has shown the way you got defy now behind a decentralized finance, health care seems to be moving on in a very accelerated rate towards that kind of concept of cloud, scale, decentralization, privacy. >>Yeah, I mean, that's a big question, what's interesting to me around that is how healthcare stakeholders are thinking about where they're providing care. So as they're buying up practices primary care specialty care and they're moving more and more outside of the brick and mortar of the health care system or partnering with your startups. That's really where I think you're going to see a larger ecosystem development, you could just look at CVS and walmart or the dollar store if they're going to be moving into health care, what does that look like? And then if you're seeking care in those settings, but then you're going to Mayo clinic or Kaiser permanente, there's so many new relationships that are part of your hair circle >>delivery is just what does that even mean now, delivery of health >>care. It's wherever you it's like the app economy you want to ride right now, you want a doctor right now, that's where we're heading its ease of use. >>This is this exciting startups, changing the game. Yes, I love it. I mean, this is what it's all about this health >>Care, this is what it's all about. And if you look at the funding right now from VCS, we're seeing so much funding pour into health care, we were just looking at some numbers and in the second quarter alone, the funding went up almost 700%. And the amount of funding that is pouring into companies like jennifer's company to really transform healthcare, 30% of it is going into telehealth. So when you talked about, you know, kind of ai at the edge, getting the right doctor the right expert at the right time, we're seeing that as a big trend in healthcare to >>well jennifer, I think the funding dynamics aside the opportunity for market total addressable market is massive when the application is being decomposed, you got front end, whether it's telemedicine, you got the different building blocks of healthcare being radically reconfigured. It's a re factoring of healthcare. Yeah, >>I think if you just think about where we're sitting today, you had to use an app to prove proof of vaccination. So this is not just national, this is a global thing to have that covid wallet. We at one record have a covid wallet. But just a couple years from now, I need more than just by covid vaccination. I need all my vaccinations. I need all my lab results. I need all my beds. It's opening the door for a new consumer behavior pattern, which is the first step to adoption for any technology. >>So somebody else covid wallet. So I need >>that was California. Did the, did a version of we just have a pen and it's pretty cool. Very handy. I should save it to my drive. But my phone, but I don't jennifer, what's the coolest thing you're working on right now because you're in the middle of all the action. >>I get very excited about the payer app is that we're working on. So I think by the end of the month we will be connected to almost to all the blues in the United States. So I'm very excited when a user comes into the one record and they're able to get their clinical data from the provider organization and then their clinical financial and formulary data from their payers because then you're getting a complete view, You're getting the records for someone who gave you care and you're getting the records from someone who paid for your care. And that's an interesting thing that's really moving towards a complete picture. So from a personal perspective that gets exciting. And then from a professional perspective, it's really working with our partners as they're using our API s to build out workflows and their applications. >>It's an api economy. I'd like to ask you to on the impact side to the patient. I hear a lot of people complaining that hey, I want to bring my records to the doctor and I want to have my own control of my own stuff. A lot of times, some doctors don't even know other historical data points about a patient that could open up a diagnosis and, or care >>or they can't even refer you to a doctor. Most doctors really only refer within a network of people that they know having a provider directory that allows doctors refer, having the data from different doctors outside of their, you know, I didn't really allows people to start thinking beyond just their little box. >>Cool. Well, great to have you on and congratulations on being in the top 10 saying this is a wonderful example of how the ecosystem where you got cloud city, your MSP. You mentioned the shout out to them jerry Miller and his team by working together the cloud gives you advantages. So I have to ask, we look at amazon cloud as an entrepreneur. It's kind of a loaded question, but I'm going to ask it. I love it. >>You always do it >>when you look at amazon, what do you see as opportunities as an entrepreneur? Because I'll see the easy ones. They have computing everything else. But like what's the, what does cloud do for you as an entrepreneur? What does it, what does it make you do? >>Yeah. So for been working with jerry since the beginning for me when I think about it, it's really the growth of our company. So when we start building, we really just thinking about it from a monolithic build and we move to microservices and amazon has been there every step of the way to support us as that. And now, you know, the things that I'm interested in are specifically health lake and anything that's NLP related that we could plug into our solution for when we get data from different sources that are coming in really unstructured formats and making it structured so that it's searchable for people and amazon does that for us with their services that we can add into the applications. >>Yeah, we announced that data health like and july it has a whole set of templates for analytics, focused on health care as well as hip hop compliance out of the box as well. >>The I think I think that's what's important is people used to think application first. Now it's creating essentially a data lake, then analytics and then what applications you build on top of that. And that's how our partners think about it and that's how we try and service them using amazon as our problem. So >>you're honing in on the value of the data and how that conflicts and then work within the whatever application requests might come >>in. Yes, >>it's interesting. You know, we had an event last month and jerry Chen from Greylock partners came on and gave a talk called castles in the cloud. He's gonna be cute before. He's a, he's a veces, they talk about moats and competitive manage so having a moat, The old school perimeter moz how cloud destroyed that. He's like, no, now the castles are in the cloud, he pointed snowflake basically data warehouse in the cloud red shifts there too. But they can be successful. And that's how the cloud, you could actually build value, sustainable value in the cloud. If you think that way of re factoring not just hosting a huge, huge, huge thing. >>I think the only thing he, this was customer service because health care is still very personal. So it's always about how you interact with the end user and how you can help me get to where they need to be going >>and what do you see that going? Because that's, that's a good point. >>I think that is a huge opportunity for any new company that wants to enter healthcare, customer service as a service in health care for all the different places that health care is going to be delivered. Maybe there's a company that I don't know about, but when they come out, I'd like to meet them. >>Yeah, I mean, I can't think of one cover that can think of right now. This is what I would say is great customer service for health care. >>And if there is one out there contacted me because I want to talk to you about AWS. >>Yeah. And you need the app from one record that make it all >>happen. That's where Omni channel customer service across all health care entities. Yeah, that's >>a great billion dollar idea for someone listening to our show right now. >>Right, alright. So saying they had to give you the opportunity to talk more because this is a great example of how the world's very agile. What's the next step for the AWS Healthcare accelerator? Are there more accelerators? Do you do it by vertical? >>What happens next? So, with the healthcare accelerator, this was our first go at the accelerator. So, this is our first set of cohorts, Of course, all 427 companies are going to get some help from a W. S. as well. We also you'll love this john We also did a space accelerator. Make sure you ask Clint about that. So we have startups that are synthesizing oxygen on mars to sending an outpost box to the moon. I mean, it's crazy what these startups are doing. Um, and then the third accelerator we started was around clean energy. So sustainability, we sold that one out to, we had folks from 66 different countries participate in that one. So these have been really successful for us. So it reinvent. When we talk again, we'll be announcing a couple of others. So right now we've got healthcare, space, clean energy and we'll be announcing a couple other accelerators moving forward. >>You know, it's interesting, jennifer the pandemic has changed even our ability to get stories. Just more stories out there now. So you're seeing kind of remote hybrid connections, ap ideas, whether it's software or remote interviews or remote connections. There's more stories being told out there with digital transformation. I mean there wasn't that many before pandemic has changed the landscape because let's face it, people were hiding some really bad projects behind metrics. But when you pull the pandemic back and you go, hey, everyone's kind of emperors got no clothes on. Those are bad projects. Those are good projects that cloud investment worked or I didn't have a cloud investment. They were pretty much screwed at that point. So this is now a new reality of like value, you can't show me value. >>It's crazy to me when I meet people who tell me like we want to move to the cloud of like, why are you not on the cloud? Like this really just blows my life. Like I don't understand why you have on prem or while you did start on the cloud, this is more for larger organizations, but younger organizations, you know, the first thing you have to do, it's set up that environment. >>Yeah. And then now with the migration plans and seeing here, uh whereas education or health care or other verticals, you've got, now you've got containers to give you that compatibility and then you've got kubernetes and you've got microservices, you've got land. Uh I mean, come on, that's the perfect storm innovation. There's no excuses in my opinion. So, you know, if you're out there and you're not leveraging it, then you're probably gonna be out of business. That's my philosophy. Thank you for coming up. Okay. Sandy, thank you. Thank you, john Okay. Any of his coverage here, summit here in D. C. I'm john ferrier. Thanks for watching. Mm >>mm mm mhm. I have been in the software and technology industry for over 12 years now, so I've had >>the opportunity

>> Narrator: From theCUBE studios in Palo Alto in Boston, connecting with thought leaders all around the world, this is a cube conversation. >> Everyone welcome to this cube conversation here in the Palo Alto cube studios. I'm John Furrier your host of theCUBE, with a great guest here, Shanthi Vigneshwaran, who is with the Office of Strategic programs in the Center for Drug Evaluation and Research within the US Food and Drug Administration, FDA, is the Informatica Intelligent Disrupter of the Year award. Congratulations, Shanthi welcome to this cube conversation. Thanks for joining me. >> Thank you for having me. >> Congratulations on being the Informatica Intelligent Disrupter of the year award. Tell us more about the organization. I see FDA everyone's probably concerned these days making sure things going faster and faster, more complex, more things are happening. Tell us about your organization and what you work on. >> FDA is huge, our organization is Center for Drug Evaluation research. And its core mission is to promote public health by ensuring the availability of safety and effective drugs. For example any drugs you go and buy it in the pharmacy today, Our administration helps in trying to approve them and make sure it's so in term of quality and integrity of the marketed products in the industry. My office is specifically Office of strategic programs whose mission is to transform the drug regulatory operations with the customer focus through analytics and informatics. They work towards the advancement for the CDERs public health mission. >> What are some of the objectives that you guys have? What are some things you guys have as your core top objectives of the CDER, the drug research group? >> The core objectives is we wanted to make sure that we are promoting a safe use of the marketed drugs. We want to make sure there's the availability of the drugs that are going to the patients are effective. And also the quality of the drugs that are being marketed are able to protect public health. >> What are some of the challenges that you guys have to take in managing the pharmaceutical safety, because I can only imagine certainly now that supply chains, tracing, monitoring, drug efficacy, safety, all these things are happening. What are some of the challenges in doing all this? >> In our office there are challenges in three different areas. One is the drug regulation challenges because as drugs are being more advanced and as there are more increasingly complex products, and there are challenging in the development area of the drugs, we wanted to make sure here we have a regulation that supports any advancement in science and technology. The other thing is also Congress is actually given new authorities and roles for the FDA to act. For example the Drug Quality and Security Act, which means any drug that's they want to track and trace all the drugs that goes to the public is they know who are the distributors, who are the manufacturers. Then you have the 21st Century Cures Act, and also the CARES Act package which was recently assigned, which also has a lot of the OTC drug regulatory modernization. Then there's also the area of globalization because just as disease don't have any borders, Product safety and quality are no longer on one country. It's basically a lot of the drugs that are being manufactured are overseas and as a result we wanted to make sure there are 300 US ports. And we want to make sure the FDA regulated shipments are coming through correctly to proper venues and everything is done correctly. Those are some the challenges we have to deal with. >> So much going on a lot of moving purchase as people say, there's always drug shortages, always demand, knowing that and tracking it. I can only imagine the world you're living in because you got to be innovative, got to be fast, got to be cutting edge, got to get the quality right. Data is super critical. And can you share take a minute to explain some of the data challenges you have to address and how you did that. Because I mean I could almost just my mind's blown just thinking about how you live it every day. Can you just share some of those challenges that you had to address and how did you do? >> Some of the key challenges we actually see is we have roughly 170,000 regulatory submissions per year. There are roughly 88,000 firm registration and product listing that comes to us, and then there are more than 2 million adverse event reports. So with all these data submissions and organization as such as us we need it, we have multiple systems where this data is acquired and each has its own criteria for validating the data. Adding to it are internal and external stakeholders also want certain rules and the way the data is being identified. So we wanted to make sure there is a robust MDM framework to make sure to cleanse and enrich and standardize the data. So that it basically make sure the trust and the availability and the consistent of the data, is being supplied to published to the CDER regulatory data users. >> You guys are dealing with- >> Otherwise like it's almost to give them a 360 degree view of the drug development lifecycle. Through each of the different phases, both pre market which is before the drug hits the market, and then after it hits the market. We still want to make sure the data we receive still supports a regulatory review and decision making process. >> Yeah, and you got to deliver a consumer product to get people at the right time. All these things have to happen, and you can see it clearly the impacts everyday life. I got to ask you that the database question 'cause the database geek inside of me is just going okay. I can only imagine the silos and the different systems and the codes, because data silos is big document. We've been reporting on this on theCUBE for a long time around, making data available automation. All these things have to happen if there's data availability. Can you just take one more minute talk about some of the challenges there because you got to break down the silos at the same time you really can't replace them. >> That's true. What we did was we did leave it more of us I mean, step back like seven years ago, when we did the data management. We had like a lot of silo systems as well. And we wanted to look at we wanted to establish a, we knew we wanted to establish a master data management. So we took a little bit more of a strategic vision. And so what we ended up saying is identifying what are the key areas of the domain that will give us some kind of a relationship. What are the key areas that will give us the 360 degree lifecycle? So that's what we did. We identified the domains. And then we took a step back and said and then we looked at what is the first domain we wanted to tackle. Because we know what are these domains are going to be. And then we were like, okay, let's take a step back and say which is the domain we do it first that will give us the most return on investment, which will make people actually look at it and say, hey, this makes sense. This data is good. So that's what we ended up looking at. We looked at it as at both ends. One is from a end user perspective. Which is the one they get the benefit out of and also from a data silo perspective which is the one data domains that are common, where there's duplication that we can consolidate. >> So that's good. You did the work up front. That's critical knowing what you want to do and get out of it. What were some of the benefits you guys got out of it. From an IT standpoint, how does that translate to the business benefits? And what was achieved? >> I think the benefits we got from the IT standpoint was a lot of the deduplication was not theirs. Which basically means like a lot of the legacy systems and all of the manual data quality work we had to do we automated it. We had bots, we also had other automation process that we actually put into work with Informatica, that actually helped us to make sure it's the cost of it actually went for us considerably. For example it used to take us three days to process submissions. Now it takes us less than 24 hours to do it, for the users to see the data. So it was a little bit more, we saw the, we wanted to look at what are the low hanging fruits where it's labor intensive and how can we improve it. That's how we acted there. >> What are some of the things that you're experiencing? I mean, like, we look back at what it was before, where it is now? Is it more agility, you more responsive to the changes? Was it an aspirin? Was it a complete transformation? Was some pain reduced? Can you share just some color commentary on kind of before the way it was before and then what you're experiencing now? >> So for us, I think before, we didn't know where the for us, I mean, I wouldn't say we didn't know it, when we have the data, we looked at product and it was just product. We looked at manufactured they were all in separate silos. But when we did the MDM domain, we were able to look at the relationship. And it was very interesting to see the relationship because we now are able to say is. for example, if there is a drug shortage during due to hurricane, with the data we have, we can narrow down and say, Hey, this area is going to be affected which means these are the manufacturing facilities in that area , that are going to be not be able to function or impacted by it. We can get to the place where the hurricane tracks we use the National Weather Service data, but it helps us to narrow down some of the challenges and we can able to predict where the next risk is going to be. >> And then before the old model, there was either a blind spot or you were ad hoc, probably right? Probably didn't have that with you. >> Yeah, before you were either blind or you're doing in a more of a reactionary not proactively. Now we are able to do a little bit more proactively. And even with I mean drug shortages and drug supply chain are the biggest benefit we saw with this model. Because, for us the drug supply chain means linking the pre and post market phases that lets us know if there's a trigger and the adverse events, we actually can go back to the pre market side and see where the traceability is who's at that truck. What are all the different things that was going on. >> This is one of the common threats I see in innovation where people look at the business model and data and look at it as a competitive advantage, in this case proactivity on using data to make decisions before things happen, less reactivity. So that increases time. I mean, that would probably you're saying, and you get there faster, if you can see it, understand it, and impact the workflows involved. This is a major part of the data innovation that's going on and you starting to see new kinds of data whereas has come out. So again, starting to see a real new changeover to scaling up this kind of concept almost foundationally. What's your thoughts just as someone who's a practitioner in the industry as you start to get this kind of feelings and seeing the benefits? What's next, what do you see happening because you haven't success. How do you scale it? What how do you guys look at that? >> I think our next is we have the domains and we actually have the practices that we work. We look at it as it's basically data always just changes. So we look at is like what are some of the ways that we can improve the data? How can we take it to the next level. Because now they talk about power. They are also warehouse data lakes. So we want to see is how can we take these domains and get that relationship or get that linkages when there is a bigger set of data that's available for us. What can we use that and it actually we think there are other use cases we wanted to explore and see what is the benefit that we can get a little bit more on the predictability to do like post market surveillance or like to look at like safety signals and other things to see what are the quick things that we can use for the business operations. >> It's really a lot more fun. You're in there using the data. You're seeing the benefits and real. This is what clouds all about the data clouds here. It's scaling. Super fun to talk about and excited. When you see the impacts in real time, not waiting for later. So congratulations. You guys have been selected and you receive recognition from Informatica as the 2020, Intelligent Disrupter of the year. congratulations. What does that mean for your organization? >> I think we were super excited about it. But one thing I can say is when we embarked on this work, like seven years ago, or so, problem was like we were trying to identify and develop new scientific methods to improve the quality of our drugs to get that 360 degree view of the drug development lifecycle. The program today enables FDA CDER to capture all the granular details of data we need for the regulatory data. It helps us to support the informed decisions that we have to make in real time sometimes or and also to make sure when there's an emergency, we are able to respond with a quick look at the data to say like, hey this is what we need to do. It also helps the teams. It recognizes all the hard work. And the hours we put into establishing the program and it helped to build the awareness within FDA and also with the industry of our political master data management is. >> It's a great reward to see the fruits of the labor and good decision making I'm sure it was a lot of hard work. For folks out there watching, who are also kind of grinding away in some cases, some cases moving faster. You guys are epitome of a supply chain that's super critical. And speed is critical. Quality is critical. A lot of days critical. A lot of businesses are starting to feel this as part of an integrated data strategy. And I'm a big proponent. I think you guys have have a great example of this. What advice would you have for other practitioners because you got data scientists, but yet data engineers now who are trying to architect and create scale, and programmability, and automation, and you got the scientists in the the front lines coming together and they all feed into applications. So it's kind of a new things go on. Your advice to folks out there, on how to do this, how to do it right, the learnings, share. >> I think the key thing I, at least for my learning experience was, it's not within one year you're going to accomplish it, It's kind of we have to be very patient. And it's a long road. If you make mistakes, you will have to go back and reassess. Even with us, with all the work we did, we almost went back a couple of the domains because we thought like, hey, there are additional use cases how this can be helpful. There are additional, for example, we went with the supply chain, but then now we go back and look at it and say like, hy, there may be other things that we can use with the supply chain not just with this data, can we expand it? How can we look at the study data or other information so that's what we try to do. It's not like you're done with MDM and that is it. Your domain is complete. It's almost like you look at it and it creates a web and you need to look at each domain and you want to come back to it and see how it is you have to go. But the starting point is you need to establish what are your key domains. That will actually drive your vision for the next four or five years. You can't just do bottom up, it's more of like a top down approach. >> That's great. That's great the insight. And again, it's never done. I mean, it's data is coming. It's not going away. It's going to be integrated. It's going to be shared. You got to scale it up. A lot of hard work. >> Yeah. >> Shanthi thank you so much for the insight. Congratulations on your receiving the Disrupter of the Year Award winner for Informatica. congratulations. Intelligence >> Yeah, thank you very much for having me. Thank you. >> Thank you for sharing, Shanthi Vigneshswaran is here, Office of Strategic programs at the Center for Drug Evaluation and Research with the US FDA. Thanks for joining us, I'm John Furrier for theCUBE. Thanks for watching. (soft music)